aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
OBJECTIVE: Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly recognized as a potential therapy for patients with highly active multiple sclerosis (MS). This study aims to assess outcome differences in disease activity in MS patients treated either with aHSCT or alemtuzumab....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164852/ https://www.ncbi.nlm.nih.gov/pubmed/33949790 http://dx.doi.org/10.1002/acn3.51366 |